Drug Search Results

CP-533,536

Alternative Names: cp-533,536, cp533,536, cp 533,536
Latest Update: 2021-04-02
Latest Update Note: PubMed Publication

Product Description

an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19250823/)

Mechanisms of Action: EP2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CP-533,536

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Fractures, Closed|Tibial Fractures

Trial	Phase	Trial Status	Disease	Primary Completion Date
2008-004183-38	P2	Completed	Unknown	2010-05-13
A3241010	P2	Completed	Tibial Fractures	2010-05-01
JapicCTI-080569	P2	Completed	Fractures, Closed\|Tibial Fractures	None

Recent News Events

Date	Type	Title
04/02/2021	PubMed	Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E2 receptor EP2 subtype.
07/01/2020	PubMed	In Vitro and In Vivo Validation of EP2-Receptor Agonism to Selectively Achieve Inhibition of Mast Cell Activity.
06/01/2020	PubMed	Distribution and Function of Prostaglandin E2 Receptors in Mouse Uterus: Translational Value for Human Reproduction.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions